keyword
MENU ▼
Read by QxMD icon Read
search

Ropinirole

keyword
https://www.readbyqxmd.com/read/29171915/targeting-hypersensitive-corticostriatal-terminals-in-restless-legs-syndrome
#1
Gabriel Yepes, Xavier Guitart, William Rea, Amy H Newman, Richard P Allen, Christopher J Earley, César Quiroz, Sergi Ferré
OBJECTIVE: The first aim was to demonstrate a previously hypothesized increased sensitivity of corticostriatal glutamatergic terminals in the rodent with brain iron deficiency (BID), a pathogenetic model of Restless Legs Syndrome (RLS). The second aim was to determine if these putative hypersensitive terminals could constitute a significant target for drugs effective in RLS, including dopamine agonists (pramipexole and ropinirole) and α2 δ ligands (gabapentin). METHODS: A recently introduced in vivo optogenetic-microdialysis approach was used, which allows the measurement of the extracellular concentration of glutamate upon local light-induced stimulation of corticostriatal glutamatergic terminals...
November 24, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28952490/photocurable-bioink-for-the-inkjet-3d-pharming-of-hydrophilic-drugs
#2
Giovanny F Acosta-Vélez, Chase S Linsley, Madison C Craig, Benjamin M Wu
Novel strategies are required to manufacture customized oral solid dosage forms for personalized medicine applications. 3D Pharming, the direct printing of pharmaceutical tablets, is an attractive strategy, since it allows for the rapid production of solid dosage forms containing custom drug dosages. This study reports on the design and characterization of a biocompatible photocurable pharmaceutical polymer for inkjet 3D printing that is suitable for hydrophilic active pharmaceutical ingredients (API). Specifically, hyaluronic acid was functionalized with norbornene moieties that, in the presence of poly(ethylene) glycol dithiol, Eosin Y as a photoinitiator, and a visible light source, undergoes a rapid step-growth polymerization reaction through thiol-ene chemistry...
January 28, 2017: Bioengineering
https://www.readbyqxmd.com/read/28950686/sleepiness-and-depression-in-parkinson-s-disease-patients-treated-with-ropinirole-and-levodopa
#3
Suk Yun Kang, Ho-Sung Ryu, Mun-Kyung Sunwoo, Sang-Jin Kim, Jong-Sam Baik, Mee-Young Park, Hyung-Eun Park, Joong-Seok Kim, Kyum-Yil Kwon, Seong-Beom Koh, Young-Eun Kim, Mi-Kyong Lee, Jong-Min Kim, Sun Ju Chung, Young-Ho Sohn
OBJECTIVE: We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson's disease (PD) with a large population. METHODS: We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson's Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30)...
September 2017: Journal of Movement Disorders
https://www.readbyqxmd.com/read/28888061/gabapentin-enacarbil-pregabalin-and-rotigotine-are-equally-effective-in-restless-legs-syndrome-a-comparative-meta-analysis
#4
REVIEW
I H Iftikhar, L Alghothani, L M Trotti
To synthesize evidence from available randomized controlled trials (RCT) to compare the efficacies of dopaminergic drugs (pramipexole, ropinirole and rotigotine) and α-2-δ ligands (gabapentin enacarbil and pregabalin) for the treatment of restless legs syndrome (RLS). We searched PubMed for all eligible RCTs. Network meta-analysis using frequentist methodology with random effect models was performed for mean changes in scores on the International RLS Study Group Rating Scale (IRLS) and for responder rates on Clinical Global Impressions-Improvement (CGI-I); analyzed as odds ratio (OR)...
September 9, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28872217/adverse-effects-produced-by-different-drugs-used-in-the-treatment-of-parkinson-s-disease-a-mixed-treatment-comparison
#5
Bao-Dong Li, Zhen-Yun Bi, Jing-Feng Liu, Wei-Jun Si, Qian-Qian Shi, Li-Peng Xue, Jing Bai
OBJECTIVE: This mixed treatment comparison is used to compare the adverse effects of eleven different drugs used to treat Parkinson's disease (PD). The drugs that we compare include the following: ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil, pergolide, and levodopa. METHODS: PubMed, EMBASE, and Cochrane Library were searched from the inception to December 2015. Our analysis combines the evidences of direct comparison and indirect comparison between various literatures...
October 2017: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/28845959/sleep-disorders-restless-legs-syndrome
#6
REVIEW
Deepa Burman
Restless legs syndrome (RLS) is a common disorder that often is underdiagnosed and undertreated. Patients with RLS describe an urge to move their legs, especially in the evenings and during periods of inactivity. The prevalence of clinically significant RLS is approximately 2% to 3% in adults in Europe and North America. RLS can be an independent disorder or may occur in conjunction with other conditions (eg, iron deficiency, pregnancy, chronic renal failure). Diagnosis is based on clinical history. Routine polysomnography typically is not recommended unless there is suspicion of other sleep disorders (eg, obstructive sleep apnea)...
September 2017: FP Essentials
https://www.readbyqxmd.com/read/28818004/identification-and-treatment-of-augmentation-in-patients-with-restless-legs-syndrome-practical-recommendations
#7
REVIEW
James Geyer, Richard Bogan
Restless legs syndrome (RLS) is a chronic disorder causing clinically significant discomfort to approximately 3% of adults. Although RLS was first identified centuries ago, our understanding of this disorder, its causes, and its treatments is still evolving. In particular, our knowledge of the potential negative effects of RLS treatments, including dopaminergic augmentation, continues to expand. Augmentation, which refers to a paradoxical treatment-related increase in RLS symptoms, has been associated with all three dopamine agonists approved for the treatment of RLS - rotigotine, pramipexole, and ropinirole...
September 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28782388/nanotechnology-based-drug-delivery-of-ropinirole-for-parkinson-s-disease
#8
Emilia Barcia, Liudmila Boeva, Luis García-García, Karla Slowing, Ana Fernández-Carballido, Yaquelyn Casanova, Sofía Negro
A new drug delivery system is developed for ropinirole (RP) for the treatment of Parkinson's disease (PD) consisting of biodegradable poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). The formulation selected was prepared with 8 mg RP and 50 mg PLGA 502. This formulation exhibited mean encapsulation efficiency of 74.8 ± 8.2%, mean particle size lower than 155 nm, the zeta potential of -14.25 ± 0.43 mV and zero-order in vitro release of RP (14.13 ± 0.17 μg/h/10 mg NPs) for 5 d...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28673860/3d-printing-of-tablets-using-inkjet-with-uv-photoinitiation
#9
Elizabeth A Clark, Morgan R Alexander, Derek J Irvine, Clive J Roberts, Martin J Wallace, Sonja Sharpe, Jae Yoo, Richard J M Hague, Chris J Tuck, Ricky D Wildman
Additive manufacturing (AM) offers significant potential benefits in the field of drug delivery and pharmaceutical/medical device manufacture. Of AM processes, 3D inkjet printing enables precise deposition of a formulation, whilst offering the potential for significant scale up or scale out as a manufacturing platform. This work hypothesizes that suitable solvent based ink formulations can be developed that allow the production of solid dosage forms that meet the standards required for pharmaceutical tablets, whilst offering a platform for flexible and personalized manufacture...
June 30, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28667675/d-512-a-novel-dopamine-d2-3-receptor-agonist-demonstrates-greater-anti-parkinsonian-efficacy-than-ropinirole-in-parkinsonian-rats
#10
David Lindenbach, Banibrata Das, Melissa M Conti, Samantha M Meadows, Aloke K Dutta, Christopher Bishop
BACKGROUND AND PURPOSE: Symptoms of Parkinson's disease are commonly managed using selective dopamine D2/3 receptor agonists, including ropinirole. While D2/3 agonists are useful in early-stage Parkinson's disease, they tend to lose efficacy in later disease stages and do not appear to modify disease progression. We have recently developed a novel 'multifunctional' compound, D-512: a high-affinity D2/3 receptor agonist with antioxidant and other neuroprotective properties that may limit Parkinson's disease progression...
September 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28615911/bupropion-and-iron-for-restless-leg-syndrome-do-they-have-efficacy-similar-to-ropinirole
#11
Samir Kumar Praharaj
No abstract text is available yet for this article.
April 2017: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/28520722/altered-detrusor-contractility-in-mptp-treated-common-marmosets-with-bladder-hyperreflexia
#12
Sara Pritchard, Michael J Jackson, Atsuko Hikima, Lisa Lione, Christopher D Benham, K Ray Chaudhuri, Sarah Rose, Peter Jenner, Mahmoud M Iravani
Bladder hyperreflexia is a common non-motor feature of Parkinson's disease. We now report on the contractility of the isolated primate detrusor strips devoid of nerve input and show that following MPTP, the amplitude and frequency of spontaneous contraction was increased. These responses were unaffected by dopamine D1 and D2 receptor agonists A77636 and ropinirole respectively. Contractions by exogenous carbachol, histamine or ATP were similar and no differences in the magnitude of noradrenaline-induced relaxation were seen in detrusor strip obtained from normal and MPTP-treated common marmosets (Callithrix jacchus)...
2017: PloS One
https://www.readbyqxmd.com/read/28457956/development-of-smart-hydrogels-of-etherified-gum-ghatti-for-sustained-oral-delivery-of-ropinirole-hydrochloride
#13
Somasree Ray, Goutam Roy, Sabyasachi Maiti, Uttam Kumar Bhattacharyya, Ayantika Sil, Ritwika Mitra
Gum Ghatti (GG) is a water soluble complex polysaccharide obtained from Anogeissus latifolia. Due to its non toxic and excellent emulsifying characteristics, it was widely used in different pharmaceutical preparations. Currently another facet was explored for its utility as release retardant polymer in oral controlled drug delivery system. As GG solely was incapable of forming microspheres therefore modification of GG to Sodium carboxymethyl (NaCMGG) derivative was done by carboxymethylation process and its gel forming capacity was explored by the use of trivalent cation (Aluminium chloride) which results into complete microbead system in a complete aqueous environment for controlled delivery of Ropinirole Hydrochloride (RHCl)...
October 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28442303/clinical-evaluation-of-ropinirole-controlled-release-formulation-at-18-24%C3%A2-mg-day-in-japanese-patients-with-parkinson-s-disease
#14
Nobutaka Hattori, Kazuko Hasegawa, Katsuaki Sato, Erika Mitsuyama, Yotaro Numachi
INTRODUCTION: There has been no clinical data on Japanese patients with Parkinson's disease with which to examine whether motor symptoms improve and to assess the safety profile after the dose of ropinirole was increased in those who had not achieved an optimal response to the ropinirole immediate-release formulation 15 mg/day or the controlled-release (CR) formulation 16 mg/day. METHODS: This was a multicenter, randomized, double-blind study, followed by an open-label, long-term study...
July 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28425644/different-effects-of-rotigotine-and-ropinirole-on-cholinergic-transmission-in-the-mouse-medial-prefrontal-cortex
#15
Kazuhiro Sohya, Kazunori O'Hashi, Hideki Toma, Hiroshi Kunugi
No abstract text is available yet for this article.
April 20, 2017: Psychogeriatrics: the Official Journal of the Japanese Psychogeriatric Society
https://www.readbyqxmd.com/read/28374775/comparison-for-efficacy-and-tolerability-among-ten-drugs-for-treatment-of-parkinson-s-disease-a-network-meta-analysis
#16
Chuanjun Zhuo, Xiaodong Zhu, Ronghuan Jiang, Feng Ji, Zhonghua Su, Rong Xue, Yuying Zhou
Parkinson's disease (PD) is a long term disorder affects the central nervous system and we aim to determine the relative efficacy of the current available drugs used in PD. Firstly, we performed a systematic review in current literature and eligible studies were retrieved from online databases, relevant data were extracted. Efficacy of these medications was assessed by different Unified Parkinson's Disease Rating Scales (UPDRS). Mean difference (MD) and odds ratio (OR) were produced by pairwise or network meta-analysis (NMA)...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28320137/what-increases-the-risk-of-malnutrition-in-parkinson-s-disease
#17
Svetlana Tomic, Vlasta Pekic, Zeljka Popijac, Tomislav Pucic, Marta Petek, Tihana Gilman Kuric, Sanja Misevic, Ruzica Palic Kramaric
Parkinson's disease (PD) patients are at a higher risk of malnutrition. The prevalence has been estimated to 0-24%, while 3%-60% of PD patients are reported to be at risk of malnutrition. To date, there is no clear explanation for malnutrition in these patients. The aim of this study was to determine the prevalence of malnutrition and to analyze factors that influence its appearance. The Mini Nutritional Assessment (MNA) was used to determine normal nutritional status; at risk of malnutrition; and already malnourished status...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28273839/parkinson-s-disease-from-pathogenesis-to-pharmacogenomics
#18
REVIEW
Ramón Cacabelos
Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28167638/effects-of-repeated-ropinirole-treatment-on-phencyclidine-induced-hyperlocomotion-prepulse-inhibition-deficits-and-social-avoidance-in-rats
#19
Amanda M Maple, Tanessa Call, Phylicia C Kimmel, Ronald P Hammer
Phencyclidine (PCP), a noncompetitive N-methyl d-aspartate (NMDA) receptor antagonist, provides the most complete pharmacologic model of schizophrenia in humans and animals. Acute PCP causes hyperlocomotion, disrupts prepulse inhibition (PPI), and increases social avoidance in rats. We have previously shown that repeated treatment with the dopamine (DA) D2-like receptor agonists, quinpirole or ropinirole, prevents agonist-induced PPI disruption. In the present study, we examined whether repeated ropinirole treatment similarly attenuates the effects of PCP in a more complete model of schizophrenia symptoms and examined the effect of repeated D2-like agonist treatment on locomotion, PPI, and social interaction after acute PCP challenge...
April 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28131725/the-5-alpha-reductase-inhibitor-finasteride-reduces-dyskinesia-in-a-rat-model-of-parkinson-s-disease
#20
Roberto Frau, Paola Savoia, Silvia Fanni, Chiara Fiorentini, Camino Fidalgo, Elisabetta Tronci, Roberto Stancampiano, Mario Meloni, Antonino Cannas, Francesco Marrosu, Marco Bortolato, Paola Devoto, Cristina Missale, Manolo Carta
Levodopa-induced dyskinesia (LID) is a disabling motor complication occurring in Parkinson's disease patients (PD) after long-term l-DOPA treatment. Although its etiology remains unclear, there is accumulating evidence that LID relies on an excessive dopamine receptor transmission, particularly at the downstream signaling of D1 receptors. We previously reported that the pharmacological blockade of 5-alpha reductase (5AR), the rate limiting enzyme in neurosteroids synthesis, rescued a number of behavioral aberrations induced by D1 receptor-selective and non-selective agonists, without inducing extrapyramidal symptoms...
May 2017: Experimental Neurology
keyword
keyword
105249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"